NCT07549945

Brief Summary

Evidence suggests that increased intravascular and interstitial fluid load in neonates with transient tachypnea of the newborn (TTN) may delay the clearance of fetal alveolar fluid (FAF). Restricted fluid (RF) therapy may accelerated FAF clearance and improve outcomes in these infants. Term and late preterm infants with TTN requiring nasal intermittent positive pressure ventilation (NIPPV) were randomized within first 2 hours after birth to receive either RF or standard fluid (SF) therapy. Primary outcomes were the duration of NIPPV and the day of discharge. Secondary outcomes included changes in weight, urine output, biochemical parameters, and monitoring of potential adverse effects.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Oct 2021

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2021

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 30, 2023

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 31, 2023

Completed
2.7 years until next milestone

First Submitted

Initial submission to the registry

April 2, 2026

Completed
22 days until next milestone

First Posted

Study publicly available on registry

April 24, 2026

Completed
Last Updated

April 24, 2026

Status Verified

April 1, 2026

Enrollment Period

1.7 years

First QC Date

April 2, 2026

Last Update Submit

April 19, 2026

Conditions

Keywords

transient tachypnea of the newbornrestricted fluid therapy,Noninvasive Ventilation

Outcome Measures

Primary Outcomes (2)

  • primary outcome

    Primary outcomes included duration of NIPPV

    "From enrollment to the end of treatment at 3 mounts"

  • Primary Outcome

    Discharge day,

    From enrollment to the end of treatment at 3 mounts

Secondary Outcomes (3)

  • secondary outcome

    "From enrollment to the end of treatment at 8 weeks"

  • Secondary Outcome

    from the time of recording to 7 days postnatal

  • Secondary outcome

    From enrollment to the end of treatment at 1 weeks"

Study Arms (2)

Restricted Fluid

EXPERIMENTAL

The total fluid volume administered on the first day was initiated at 50 mL/kg/day in the RF group for infants with a gestational age of 34⁰/₇-36⁶/₇ weeks. The total fluid volume administered on the first day was initiated at 40 mL/kg/day in the RF group for infants with agestational age of ≥37 weeks

Procedure: restricted fluid regimen

Standart Fluid

ACTIVE COMPARATOR

The total fluid volume administered on the first day was initiated at 70 mL/kg/day in the RF group for infants with a gestational age of 34⁰/₇-36⁶/₇ weeks. 60 mL/kg/day in gestational age of ≥37 weeks

Procedure: Standart fluid

Interventions

The total fluid volume administered on the first day was initiated at 50 mL/kg/day in the RF group for infants with a gestational age of 34⁰/₇-36⁶/₇ weeks. 40 mL/kg/day in gestational age of ≥37 weeks

Restricted Fluid

70 mL/kg/day in the standart fluid group for infants with a gestational age of 34⁰/₇-36⁶/₇ weeks, whereas it was initiated at 60 mL/kg/day in thestandart fluid group for infants with a gestational age of ≥37 weeks.

Standart Fluid

Eligibility Criteria

Age34 Weeks - 42 Weeks
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Neonates born at our hospital with a gestational age of ≥34⁰/⁷ weeks who were diagnosed with TTN were included in the study.

You may not qualify if:

  • Infants with severe congenital anomalies, those who required intubation in the delivery room or upon admission to the NICU, infants born through meconium-stained amniotic fluid, perinatally asphyxiated infants, infants with suspected sepsis based on risk factors or clinical findings, and infants diagnosed with TTN who did not require NIV were not included from the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hitit University Erol Olçok Training and Research Hospital

Çorum, Çorum, 19100, Turkey (Türkiye)

Location

Related Publications (4)

  • Gupta N, Bruschettini M, Chawla D. Fluid restriction in the management of transient tachypnea of the newborn. Cochrane Database Syst Rev. 2021 Feb 18;2(2):CD011466. doi: 10.1002/14651858.CD011466.pub2.

    PMID: 33599990BACKGROUND
  • Sardar S, Pal S, Mishra R. A randomized controlled trial of restricted versus standard fluid management in late preterm and term infants with transient tachypnea of the newborn. J Neonatal Perinatal Med. 2020;13(4):477-487. doi: 10.3233/NPM-190400.

    PMID: 32444567BACKGROUND
  • Dehdashtian M, Aramesh MR, Melekian A, Aletayeb MH, Ghaemmaghami A. Restricted versus Standard Maintenance Fluid Volume in Management of Transient Tachypnea of Newborn: A Clinical Trial. Iran J Pediatr. 2014 Oct;24(5):575-80. Epub 2014 Oct 1.

    PMID: 25793064BACKGROUND
  • Stroustrup A, Trasande L, Holzman IR. Randomized controlled trial of restrictive fluid management in transient tachypnea of the newborn. J Pediatr. 2012 Jan;160(1):38-43.e1. doi: 10.1016/j.jpeds.2011.06.027. Epub 2011 Aug 11.

    PMID: 21839467BACKGROUND

MeSH Terms

Conditions

Transient Tachypnea of the Newborn

Condition Hierarchy (Ancestors)

Respiratory Distress Syndrome, NewbornRespiratory Distress SyndromeLung DiseasesRespiratory Tract DiseasesRespiration DisordersTachypneaInfant, Premature, DiseasesInfant, Newborn, DiseasesCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesSigns and Symptoms, RespiratorySigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • İsmail K Gökçe, Assoc.prof

    Hitit University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
CROSSOVER
Model Details: Infants with TTN requiring NIPPV were randomized within the first two hours of life to either the RF group or the standard fluid (SF) group using the sealed opaque envelope method. To ensure homogeneous distribution of infants with similar gestational ages between the groups, infants born at 34⁰/₇-36⁶/₇ weeks and those born at ≥37 weeks of gestation were randomized separately using a stratified randomization approach. The total fluid volume administered on the first day was initiated at 50 mL/kg/day in the RF group and 70 mL/kg/day in the SF group for infants with a gestational age of 34⁰/₇-36⁶/₇ weeks, whereas it was initiated at 40 mL/kg/day in the RF group and 60 mL/kg/day in the SF group for infants with a gestational age of ≥37 weeks.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assoc. Prof

Study Record Dates

First Submitted

April 2, 2026

First Posted

April 24, 2026

Study Start

October 1, 2021

Primary Completion

May 30, 2023

Study Completion

July 31, 2023

Last Updated

April 24, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share

Locations